SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?

Endocr Pract. 2015 Dec;21(12):1442-4. doi: 10.4158/EP151013.CO. Epub 2015 Oct 20.
No abstract available

Publication types

  • Comment

MeSH terms

  • Canagliflozin / administration & dosage*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Glucagon-Like Peptide 1 / agonists*
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Male
  • Sodium-Glucose Transporter 2 Inhibitors*

Substances

  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin
  • Glucagon-Like Peptide 1